title: [Justification to health managers: cost-benefit of osteoporosis management].
abstract: Medicines are strictly regulated and controlled until they reach the patients. Once in the market, the mechanisms governing their use are very complex due to the large number of actors playing different roles. It is necessary to extend an evaluation culture among all involved and to make economic analysis a structured part of decisions made by physicians and health managers. Since physicians occupy a central place in this market of medicines, it is necessary that they assume their responsibility by actively participating in this evaluation.
authors.affiliation: Subdirección General de Medicamentos de Uso Humano, Agencia Española de Medicamentos y Productos Sanitarios, Madrid, España. chernandezg@aemps.es
authors.forename: César
authors.initials: C
authors.lastname: Hernández-García
mesh_terms: D003362:Cost-Benefit Analysis; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000191:economics*; D010593:Pharmaceutical Services / Q000458:organization & administration*